Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
51.42/63.32
|
|
Enterprise Value
23.85B
|
| Balance Sheet |
|
Book Value Per Share
4.80
|
| Cash Flow |
|
Cash Flow Yield
0.05
|
| Income Statement |
|
Total Revenue
245.88B
|
|
Operating Revenue Per Share
3.85
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%).Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand nameand earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries. |

14.38 
